The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Abstract
Environmental and genetic aspects are reflected in the development of prostate cancer. In this context, there is growing evidence that chronic inflammation is involved in the regulation of cellular events in prostate carcinogenesis, including disruption of the immune response and regulation of the tumour microenvironment. One of the best surrogates of chronic inflammation in prostate cancer is interleukin 6 ( IL ‐6). Serum IL ‐6 levels are elevated in patients with untreated metastatic or castration‐resistant prostate cancer ( CRPC ) and correlate negatively with tumour survival and response to chemotherapy. Via multiple signal pathways including the J anus tyrosine family kinase ( JAK )‐signal transducer and activator of transcription ( STAT ) pathway, the extracellular signal‐regulated kinase 1 and 2 ( ERK 1/2)‐mitogen activated protein kinase ( MAPK ) pathway, and the phosphoinositide 3‐kinase ( PI 3‐ K ) pathway, IL ‐6 is able to promote prostate cancer cell proliferation and inhibit apoptosis in vitro and in vivo . IL ‐6 is associated with aggressive prostate cancer phenotype and may be involved in the metastatic process through regulation of epithelial–mesenchymal transition ( EMT ) and homing of cancer cells to the bone. A substantial body of evidence suggests that IL ‐6 plays a major role in the transition from hormone‐dependent to CRPC , most notably through accessory activation of the androgen receptor. Collectively, these data have stimulated the development of agents targeting IL ‐6 signalling pathways. A chimeric anti‐ IL ‐6 monoclonal antibody has been tested in clinical trials, with mixed results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
Chronic inflammation and cancer.
Shacter, E. B., & Weitzman, S. A. (2002) · PubMed · Cited by 694
Rose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010) · Nature · doi:10.1038/nature08782 · Cited by 639
Prostate cancer and inflammation: the evidence
Sfanos, K. S., & De Marzo, A. M. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04033.x · Cited by 612
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0785 · Cited by 596
Chronic Inflammation and Cancer
Oshima, M. (2013) · 肥満研究 · Cited by 580
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., & Drake, C. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5164 · Cited by 427
ADLER, H. L., McCURDY, M. A., KATTAN, M. W., TIMME, T. L., SCARDINO, P. T., & THOMPSON, T. C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 386
Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer
Giri, D., Ozen, M., & Ittmann, M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63067-2 · Cited by 334
Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22862 · Cited by 316
Okamoto, M., Lee, C., & Oyasu, R. (1997) · PubMed · Cited by 304
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
Qiu, Y., Ravi, L., & Kung, H.-J. (1998) · Nature · doi:10.1038/30012 · Cited by 280
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261
Characterization of the role of IL-6 in the progression of prostate cancer
Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M., & Simons, J. W. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h · Cited by 231
Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.
Lee, S. O., Lou, W., Hou, M., Miguel, F. D., Gerber, L., & Gao, A. C. (2003) · PubMed · Cited by 215
Bellido, T. (1997) · Endocrinology · doi:10.1210/en.138.9.3666 · Cited by 212
Dorff, T. B., Goldman, B., Pinski, J. K., Mack, P. C., Lara, P. N., Van Veldhuizen, P. J., Quinn, D. I., Vogelzang, N. J., Thompson, I. M., & Hussain, M. H. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 212
Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197
Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., Beraldi, E., Bazov, J., Fazli, L., Chi, K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3979 · Cited by 194
Deeble, P. D., Murphy, D. J., Parsons, S. J., & Cox, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8471-8482.2001 · Cited by 185
Wegiel, B., Bjartell, A., Culig, Z., & Persson, J. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23261 · Cited by 179
Kroon, P., Berry, P. A., Stower, M. J., Rodrigues, G., Mann, V. M., Simms, M., Bhasin, D., Chettiar, S., Li, C., Li, P.-K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0874 · Cited by 175
George, D. J., Halabi, S., Shepard, T. F., Sanford, B., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1560 · Cited by 168
Domingo-Domenech, J., Oliva, C., Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C., Tapia, M., Campás, C., Dang, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2767 · Cited by 166
Fujimoto, M., Nakano, M., Terabe, F., Kawahata, H., Ohkawara, T., Han, Y., Ripley, B., Serada, S., Nishikawa, T., Kimura, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903314 · Cited by 160
IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
Rojas, A., Liu, G., Coleman, I., Nelson, P. S., Zhang, M., Dash, R., Fisher, P. B., Plymate, S. R., & Wu, J. D. (2011) · Oncogene · doi:10.1038/onc.2010.605 · Cited by 155
CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCER
Wise, G. J., Marella, V. K., Talluri, G. S., & Shirazian, D. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67289-8 · Cited by 152
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148
The evolving biology and treatment of prostate cancer
Taichman, R. S., Loberg, R. D., Mehra, R., & Pienta, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31791 · Cited by 146
Santer, F. R., Malinowska, K., Čulig, Z., & Cavarretta, I. T. R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0200 · Cited by 120
Smith, P. C., & Keller, E. T. (2001) · The Prostate · doi:10.1002/pros.1080 · Cited by 118
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 116
Ebelt, K., Babaryka, G., Figel, A.-M., Pohla, H., Büchner, A., Stief, C. G., Eisenmenger, W., Kirchner, T., Schendel, D. J., & Noeßner, E. (2007) · The Prostate · doi:10.1002/pros.20661 · Cited by 115
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Chun, J. Y., Nadiminty, N., Dutt, S. S., Lou, W., Yang, J. C., Kung, H., Evans, C. P., & Gao, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0640 · Cited by 109
Steiner, H., Godoy‐Tundidor, S., Rogatsch, H., Berger, A. P., Fuchs, D., Comuzzi, B., Bartsch, G. H., Hobisch, A., & Čulig, Z. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63859-x · Cited by 97
Prostate inflammation and its potential impact on prostate cancer: A current review
Haverkamp, J. M., Charbonneau, B., & Ratliff, T. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21536 · Cited by 96
Wu, C., Hsieh, C., Lin, C., Chen, W., Hong, J., & Chen, M. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0916-x · Cited by 91
Lee, S. O., Chun, J. Y., Nadiminty, N., Lou, W., & Gao, A. C. (2007) · The Prostate · doi:10.1002/pros.20553 · Cited by 87
Lü, Y., Zhang, J., Dai, J., Dehne, L. A., Mizokami, A., Yao, Z., & Keller, E. T. (2004) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-0056-6 · Cited by 62
Cardillo, M. R., & Ippoliti, F. (2006) · PubMed · Cited by 57
Orchiectomy Increases Bone Marrow Interleukin-6 Levels in Mice
Zhang, J., Pugh, T. D., Stebler, B. S., Ershler, W. B., & Keller, E. T. (1998) · Calcified Tissue International · doi:10.1007/s002239900421 · Cited by 53
Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior
Gueron, G., Siervi, A. D., & Vazquez, E. S. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.64 · Cited by 52
Steiner, H., Berger, A. P., Godoy‐Tundidor, S., Bjartell, A. S., Lilja, H. G., Bartsch, G., Hobisch, A., & Čulig, Z. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.033 · Cited by 52
Morrissey, C. M., Lai, J. S., Brown, L. G., Wang, Y.-C., Roudier, M. P., Coleman, I. M., Gulati, R., Vakar‐Lopez, F., True, L. D., Corey, E., et al. (2009) · The Prostate · doi:10.1002/pros.21075 · Cited by 43
Steiner, H., Cavarretta, I. T. R., Moser, P. L., Berger, A. P., Bektić, J., Dietrich, H., Zaki, M. H., Nakada, M. T., Hobisch, A., Nemeth, J. A., et al. (2006) · The Prostate · doi:10.1002/pros.20492 · Cited by 41
Sivashanmugam, P., Tang, L., & Daaka, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313776200 · Cited by 40
Shariat, S. F., Chromecki, T. F., Hoefer, J., Barbieri, C. E., Scherr, D. S., Karakiewicz, P. I., Roehrborn, C. G., Montorsi, F., Čulig, Z., & Cavarretta, I. T. R. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.06.048 · Cited by 17
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109130 · Cited by 401
Krause, M., Dubrovska, A., Linge, A., & Baumann, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.002 · Cited by 305
Metadata
- Authors
- Nguyen, D. P., Li, J., & Tewari, A. K.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2014-06
- Volume
- 113
- Issue
- 6
- Pages
- 986-992
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1581834767
- Cited by
- 359
- References
- 54
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.